Best Lab Equipment

Here are some more information for Hematology Analyzer:

Medical laboratories need hematology analyzers for the analysis of blood cells and count, platelet enumerations and other related procedures. These analyzers have therefore become an indispensable part of laboratory procedures. Both new and refurbished models of these analyzers are available to cater to the requirements of the laboratories of all sizes.

Some of the leading manufacturers of hema analyzers include Abbott Diagonostics, Beckman Coulter, Horiba ABX, Clay Adams, and Mindray. The new and refurbished blood analysis devices they supply offer simple operation, results within seconds, high resolution color LCD monitor with histogram displays, time saving capabilities, automatic cleaning modes and minimal maintenance. Reagents, controls, and consumables and service contracts are available for most models.

New Hematology Analyzers - Advantages

The main benefit of using brand new hematology analyzers is that they incorporate the latest technology. New equipment also performs better than used models and the risk of breakdowns are less. Many dealers offer on-site maintenance and repair services. Accessories and parts are also easily available.

Refurbished Models at Reduced Rates

Buying a new model of hematology analyzer can be a big decision for small and medium labs. Refurbished models of these analyzers are great options for laboratories with limited budgets, and enable them to take advantage of the advanced technology at a fraction of the cost. The used equipment is thoroughly inspected, repaired and reassembled to original manufacturer specifications to ensure that it performs as well as new. It is then recertified for use. One of the greatest advantages is that refurbished hematology analyzers are available at highly reduced rates, while offering quality features and stable performance. Additional benefits include extended warranty, service contracts, on time delivery, material service visits and in-house service.

Buy from Established Dealers

Established dealers in lab equipment have a large inventory of different models and brands of new and refurbished analyzers. The offer excellent customer support and guarantee the quality of the products they supply.

Block Scientific is the affordable source of fine Medical Laboratory Equipment like Centrifuges, Chemistry Analyzers, Hematology Analyzers, Blood Gas Analyzers and more.

Health: Terra med Alliance News FDA Approved Leukemia Drugs Shows Promise In Ovarian Cancer Cells

Terra med Alliance News: The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

Terra med Alliance News: The drug, when paired with a chemotherapy regimen, was even more effective in fighting ovarian cancer in cell lines in which signaling of the Src family kinases, associated with the deadly disease, is activated.

The study appears in the Nov. 10, 2009 edition of the British Medical Journal.

Ovarian cancer, which will strike 21,600 women this year and kill 15,500, causes more deaths than any other cancer of the female reproductive system. Few effective therapies for ovarian cancer exist, so it would be advantageous for patients if a new drug could be found that fights the cancer, said Gottfried Konecny, an assistant professor of hematology/oncology, a Jonsson Cancer Center researcher and first author of the study.

"I think Sprycel could be a potential additional drug for treating patients with Src dependent ovarian cancer," Konecny said. "It is important to remember that this work is only on cancer cell lines, but it is significant enough that it should be used to justify clinical trials to confirm that women with this type of ovarian cancer could benefit."

Recent gene expression studies have shown that about one-third of women have ovarian cancers with activated Src pathways, so the drug could potentially help 7,000 ovarian cancer patients every year.

In this study, the UCLA team tested the drug against 34 ovarian cancer cell lines and they conducted genetic analysis on all cell lines. Through these analyses, the researchers were able to identify genes that predict response to Sprycel. If the work is confirmed in human studies, it may be possible to test patients for Src activation and select those who would respond prior to treatment, personalizing their care.

"We were able to identify markers in the pre-clinical setting that would allow us to predict response to Sprycel," Konecny said. "These may help us in future clinical trials in selecting patients for studies of the drug."

Sprycel is what is known as a "dirty" kinase inhibitor, meaning it inhibits more than one pathway. Konecny said it also inhibits the focal adhesion kinase and ephrin receptor, also associated with ovarian cancer.

The next step, Konecny said, would be to test the drug on women with ovarian cancer in a clinical trial. The tissue of responders would then be analyzed to determine if the Src and other pathways were activated. If that is confirmed, it would further prove that Sprycel could be used to fight ovarian cancer. In studies, women would be screened before entering a trial and only those with Src dependent cancers could be enrolled to provide further evidence, Konecny said, much like the studies of the molecularly targeted breast cancer drug Herceptin enrolled only women who had HER-2 positive disease.

"Herceptin is different because we knew in advance that the only worked in women with HER-2 amplification," he said. "In this case, we don't clearly know that yet. The data reassure us that the drug works where the targets are over-expressed but we need more testing to confirm this."

The tests combining the drug with chemotherapy are significant because chemotherapy currently is the first line treatment for ovarian cancer patients following surgery. Because Sprycel proved to have a synergistic effect when combined with chemotherapy -- both made the other work better -- it may be possible to add the targeted therapy as a first line treatment if its efficacy is confirmed in future studies, adding a new tool to an oncologist's arsenal. Adapted from materials provided by University of California - Los Angeles, via EurekAlert!, a service of AAAS.

Terra med Alliance is a non-profit organization in the battle against leukemia  helps  children living with cancer and their families. Our goal is to make sure children battling cancer know they are not alone. For more information please visit www.terramedalliance.org.  Email at contact@terramedalliance.org

About the Author

Terra med Alliance is a non-profit organization in the battle against leukemia helps children living with cancer and their families. Our goal is to make sure children battling cancer know they are not alone. For more information please visit www.terramedalliance.org. Email at contact@terramedalliance.org

Which one is better Sysmex XE-2100 or Beckman Coulter HMX?

Hematology Analyzer

The Sysmex XE-2100 is an automated hematological analyser, used to quickly perform full blood and reticulocyte counts.

The Beckman Coulter HMX is a more powerful (and more expensive) automated hematology analyzer, which can also perform reticulocyte and white blood cell counts, distinguishing lymphocytes, monocytes, neutrophils, eosinophils and basophils.

Clarient's Ovotax test may help improve patients’ response to taxane therapy
Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study shows that Clarient's Ovotax™ assay may effectively predict which ovarian cancer patients will respond favorably to taxane therapy and could, therefore, be spared the potential side effects of this rigorous and sometimes toxic ...

Thanks for visiting!